logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Atezolizumab/ipilimumab/pembrolizumabColitis and ulcer: 3 case reports

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2018年 / 1699卷 / 1期
关键词:
D O I:
10.1007/s40278-018-45309-8
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:40 / 40
相关论文
共 50 条
  • [31] Atezolizumab/bevacizumabVarious toxicities: 3 case reports
    Reactions Weekly, 2023, 1944 (1) : 125 - 125
  • [32] Lenvatinib/pembrolizumabColitis and hepatitis: 2 case reports
    Reactions Weekly, 2018, 1715 (1) : 156 - 156
  • [33] Ipilimumab/nivolumab/vemurafenibUveitis: 3 case reports
    Reactions Weekly, 2016, 1606 (1) : 93 - 93
  • [34] Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports
    Reactions Weekly, 2021, 1871 (1) : 216 - 216
  • [35] Ipilimumab/nivolumabVarious toxicities: 3 case reports
    Reactions Weekly, 2017, 1643 (1) : 167 - 167
  • [36] Ipilimumab/nivolumabVarious toxicities: 3 case reports
    Reactions Weekly, 2020, 1816 (1) : 192 - 192
  • [37] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
    Reactions Weekly, 2024, 2037 (1) : 222 - 222
  • [38] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 3 case reports
    Reactions Weekly, 2022, 1909 (1) : 303 - 303
  • [39] Ipilimumab/nivolumab/pembrolizumabThyroiditis: 3 case reports
    Reactions Weekly, 2019, 1748 (1) : 268 - 268
  • [40] Ipilimumab/pembrolizumabVarious toxicities: 3 case reports
    Reactions Weekly, 2016, 1631 (1) : 98 - 98
← 12345 →